Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 8/20 | 0.47 |
| ▸ | SPHK1 | Q9NYA1 | 5/20 | 0.46 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.43 |
| ▸ | CASP2 | P42575 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.40 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.40 |
| ▸ | NAAA | Q02083 | 1/20 | 0.40 |
| ▸ | RRM1 | P23921 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1428105 | 1.00 | EPHX1 (0.47) | EPHX1SPHK1SPHK2CASP2MEN1 | |
| SCHEMBL4111428 | 1.00 | EPHX1 (0.47) | EPHX1SPHK1SPHK2CASP2MEN1 | |
| Polihexanide SCHEMBL45011 | 1.00 | EPHX1 (0.47) | EPHX1SPHK1SPHK2CASP2MEN1 | |
| SCHEMBL3921623 | 1.00 | EPHX1 (0.47) | EPHX1SPHK1SPHK2CASP2MEN1 | |
| SCHEMBL5133441 | 1.00 | EPHX1 (0.47) | EPHX1SPHK1SPHK2CASP2MEN1 | |
| Hydrochloric Acid SCHEMBL9667167 | 0.98 | SPHK1 (0.49) | EPHX1SPHK1SPHK2CASP2MEN1 | |
| Hydrochloric Acid SCHEMBL8898546 | 0.98 | SPHK1 (0.49) | EPHX1SPHK1SPHK2CASP2MEN1 | |
| Polihexanide SCHEMBL115297 | 0.98 | SPHK1 (0.49) | EPHX1SPHK1SPHK2CASP2MEN1 | |
| Polihexanide SCHEMBL6770315 | 0.98 | EPHX1 (0.45) | EPHX1SPHK1SPHK2CASP2MEN1 | |
| Polihexanide SCHEMBL8515092 | 0.98 | SPHK1 (0.49) | EPHX1SPHK1SPHK2CASP2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 612 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012036392-A3 | HUMAN ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR FAB ANTIBODY AND A PHARMACEUTICAL COMPOSITION FOR TREATING TUMOURS COMPRISING THE SAME | 주식회사 아이지세라피 (KR) | 2012-05-10 | — | — | WO | claimed |
| EP-1930376-B1 | CURABLE COMPOSITION | KANEKA CORP (JP) | 2011-12-07 | — | — | EP | claimed |
| CN-113347793-B | Method for manufacturing printed wiring board | 味之素株式会社 | 2026-05-19 | — | — | CN | disclosed |
| EP-4734673-A1 | WIRING BOARD | Resonac Corporation (JP) | 2026-04-29 | — | — | EP | disclosed |
| US-20260109849-A1 | EPOXY RESIN COMPOSITION, RESIN PASTE, FILM-TYPE ADHESIVE, PRINTED WIRING BOARD, SEMICONDUCTOR CHIP PACKAGE, AND ELECTRONIC DEVICE | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2026-04-23 | — | — | US | disclosed |
| EP-3971920-B1 | RESIN COMPOSITION | AJINOMOTO KK (JP) | 2026-04-01 | — | — | EP | disclosed |
| EP-4711416-A1 | RESIN COMPOSITION AND USE THEREOF | TOKUYAMA CORPORATION (JP) | 2026-03-18 | — | — | EP | disclosed |
| EP-4692247-A1 | CURABLE COMPOSITION | KANEKA CORPORATION (JP) | 2026-02-11 | — | — | EP | disclosed |
| US-20260022211-A1 | CURABLE COMPOSITION | KANEKA CORPORATION (JP) | 2026-01-22 | — | — | US | disclosed |
| EP-4679461-A2 | RESIN COMPOSITION AND PRODUCTION METHOD OF THE SAME | AJINOMOTO CO., INC. (JP) | 2026-01-14 | — | — | EP | disclosed |
| EP-4180482-B1 | MOISTURE-CURABLE COMPOSITION | NITTO KASEI CO LTD (JP) | 2025-12-03 | — | — | EP | disclosed |
| US-20090182099-A1 | CURABLE COMPOSITION | KANEKA CORPORATION (JP) | 2009-07-16 | — | — | US | disclosed |
| US-20090182091-A1 | CURABLE COMPOSITION | KANEKA CORPORATION (JP) | 2009-07-16 | — | — | US | disclosed |
| US-20090171025-A1 | CURABLE COMPOSITION | KANEKA CORPORATION (JP) | 2009-07-02 | — | — | US | disclosed |
| EP-1992665-A1 | CURABLE COMPOSITION | Kaneka Corporation (JP) | 2008-11-19 | — | — | EP | disclosed |
| EP-1990370-A1 | CURABLE COMPOSITION | Kaneka Corporation (JP) | 2008-11-12 | — | — | EP | disclosed |
| EP-1988127-A1 | CURABLE COMPOSITION | Kaneka Corporation (JP) | 2008-11-05 | — | — | EP | disclosed |
| EP-1985666-A1 | CURABLE COMPOSITION | Kaneka Corporation (JP) | 2008-10-29 | — | — | EP | disclosed |
| EP-1939257-A1 | CURABLE COMPOSITION | Kaneka Corporation (JP) | 2008-07-02 | — | — | EP | disclosed |
| EP-1930376-A1 | CURABLE COMPOSITION | Kaneka Corporation (JP) | 2008-06-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260109849-A1 | EPOXY RESIN COMPOSITION, RESIN PASTE, FILM-TYPE ADHESIVE, PRINTED WIRING BOARD, SEMICONDUCTOR CHIP PACKAGE, AND ELECTRONIC DEVICE | ASH2L, DOT1L, ASH1L | EPHX1 163/4885SPHK1 3511/4885SPHK2 3611/4885 |
| US-20260022211-A1 | CURABLE COMPOSITION | H1-4, H1-0, H1-2 | EPHX1 3313/4885SPHK1 2867/4885SPHK2 2794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.